Claims
- 1. A method of treating a dysphoric condition characterized by anxiety, depression or excitability in a warm-blooded animal in need of such treatment comprising administering, enterally or parenterally, to said animal a therapeutically effective amount for said condition of a compound of the formula ##STR6## which is R-(-)-alpha-[(methylamino)methyl]-9,10-ethanoanthracene-9(10H)-ethanol, substantially free of the S-(+) antipode thereof, or a pharmaceutically acceptable salt thereof.
- 2. A method of treating a psychovegetative disorder stemming from depression or anxiety in a warm blooded animal in need of such treatment comprising administering, enterally or parenterally, to said animal a therapeutically effective amount for said condition of a compound of the formula ##STR7## which is R-(-)-alpha-[(methylamino)methyl]-9,10-ethanoanthracene-9(10H)-ethanol, substantially free of the S-(+) antipode thereof, or a pharmaceutically acceptable salt thereof.
- 3. A method of treating a psychosomatic disorder stemming from depression or anxiety in a warm-blooded animal in need of such treatment comprising administering, enterally or parenterally, to said animal a therapeutically effective amount for said condition of a compound of the formula ##STR8## which is R-(-)-alpha-[ (methylamino)methyl]-9,10-ethanoanthracene-9(10H)-ethanol, substantially free of the S-(-) antipode thereof, or a pharmaceutically acceptable salt thereof.
- 4. The method of claim 1 wherein said compound or pharmaceutically acceptable salt thereof is administered in an amount of from 0.05 and 3.0 mg/kg/day.
- 5. The method of claim 2 wherein said compound or pharmaceutically acceptable salt thereof is administered in an amount of from 0.05 and 3.0 mg/kg/day.
- 6. The method of claim 3 wherein said compound or pharmaceutically acceptable salt thereof is administered in an amount of from 0.05 and 3.0 mg/kg/day.
- 7. The method of claim 1 wherein said compound or pharmaceutically acceptable salt thereof is administered in an amount of from 10 and 150 mg/day.
- 8. The method of claim 2 wherein said compound or pharmaceutically acceptable salt thereof is administered in an amount of from 10 and 150 mg/day.
- 9. The method of claim 3 wherein said compound or pharmaceutically acceptable salt thereof is administered in an amount of from 10 and 150 mg/day.
Priority Claims (2)
Number |
Date |
Country |
Kind |
1046/79 |
Feb 1979 |
CHX |
|
93/80 |
Jan 1980 |
CHX |
|
Parent Case Info
This is a divisional of application Ser. No. 274,907, filed on June 18, 1981, now abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4017542 |
Wilhelm et al. |
Apr 1977 |
|
Non-Patent Literature Citations (2)
Entry |
Burger, "Medicinal Chemistry", 3rd Ed., Part I, pp. 81-85 and 100-103 (1970). |
E. Uschin et al., Frontiers in Neuropsychiat Research Ed. MacMillan, pp. 121-134 (1983). |
Divisions (1)
|
Number |
Date |
Country |
Parent |
274907 |
Jun 1981 |
|